To squeeze or not to squeeze. The ARISE-FLUIDS trial
This review discusses the ARISE-FLUIDS trial, which directly compared two distinct resuscitation strategies in septic shock patients presenting to the emergency department. Specifically, it pitted an early vasopressor approach combined with restricted fluid administration against a strategy involving higher initial fluid volumes followed by later vasopressor initiation. The key finding reported is that neither of these management paradigms demonstrated superiority regarding the primary endpoint of days alive at day 90. This suggests that current resuscitation guidelines may benefit from re-evaluation, as the trial did not support a clear advantage for early vasopressors paired with fluid restriction over more aggressive initial fluid loading.
This review discusses the ARISE-FLUIDS trial, which directly compared two distinct resuscitation strategies in septic shock patients presenting to the emergency department. Specifically, it pitted an early vasopressor approach combined with restricted fluid administration against a strategy involving higher initial fluid volumes followed by later vasopressor initiation. The key finding reported is that neither of these management paradigms demonstrated superiority regarding the primary endpoint of days alive at day 90. This suggests that current resuscitation guidelines may benefit from re-evaluation, as the trial did not support a clear advantage for early vasopressors paired with fluid restriction over more aggressive initial fluid loading.
Show moreShow less
When managing septic shock in the ED, remember that the ARISE-FLUIDS data does not favor an early vasopressor approach combined with restricted fluids over higher initial fluid volumes. This suggests a need for judicious use of both agents and careful titration rather than rigidly adhering to one protocol or the other. Always consider the patient's hemodynamic status when deciding on the balance between aggressive fluid resuscitation and timely pressor support.